Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase

Molecular Cancer Therapeutics

Volumn 10, Issue 8, 2011, Pages 1327-1336

  Chen, Chun Te ^a,b   Yamaguchi, Hirohito ^a   Lee, Hong Jen ^a,b   Du, Yi ^a,b   Lee, Heng Huan ^a,b   Xia, Weiya ^a   Yu, Wen Hsuan ^a,b   Hsu, Jennifer L ^a,c   Yen, Chia Jui ^a   Sun, Hui Lung ^a   Wang, Yan ^a   Yeh, Edward T H ^a   Hortobagyi, Gabriel N ^a   Hung, Mien Chie ^a,b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ENDOSTATIN CYTOSINE DEAMINASE URACIL PHOSPHORIBOSYLTRANSFERASE FUSION PROTEIN; FLUCYTOSINE; FLUOROURACIL; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER INVASION; CANCER MODEL; CARDIOTOXICITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG TARGETING; DRUG TUMOR LEVEL; ENDOTHELIUM CELL; HUMAN; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOSINE DEAMINASE; DISEASE MODELS, ANIMAL; ENDOSTATINS; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PENTOSYLTRANSFERASES; PRODRUGS; RECOMBINANT FUSION PROTEINS;

EID: 80051587422     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-1117     Document Type: Article

References (42)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86. (Pubitemid 46505878)
2. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39. (Pubitemid 37328908)
3. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-6.
4. Kramer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 2007;32:1-14. (Pubitemid 46213936)
5. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332-44. (Pubitemid 46652481)
6. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
8. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-75. (Pubitemid 350007692)
9. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-9. (Pubitemid 27098025)
10. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009;6:569-79.
11. Kerbel RS. Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast 2009;18 Suppl 3:S41-7.
12. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
13. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475-85. (Pubitemid 46809172)
14. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991;13:31-6. (Pubitemid 21892580)
15. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85. (Pubitemid 28015876)
16. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A 2003;100:4766-71. (Pubitemid 36457804)
17. Yang L, Wang JW, Sun Y, Zhu YZ, Liu XQ, Li WL, et al. [Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi 2006;28:138-41.
18. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20:3792-803.
19. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24:3555-61. (Pubitemid 46630526)
20. Fu Y, Tang H, Huang Y, Song N, Luo Y. Unraveling the mysteries of endostatin. IUBMB Life 2009;61:613-26.
21. Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999;17:2180-9. (Pubitemid 29318851)
22. Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V, et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 2001;8:1547-54. (Pubitemid 33061893)
23. Ramnaraine M, Pan W, Goblirsch M, Lynch C, Lewis V, Orchard P, et al. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res 2003;63:6847-54. (Pubitemid 37322967)
24. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000;60:3813-22. (Pubitemid 32204573)
25. Ou-Yang F, Lan KL, Chen CT, Liu JC, Weng CL, Chou CK, et al. Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells. Cancer Res 2006;66:378-84. (Pubitemid 43166045)
26. Romano P, Manniello A, Aresu O, Armento M, Cesaro M, Parodi B. Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines. Nucleic Acids Res 2009;37:D925-32.
27. Huang X, Wong MK, Zhao Q, Zhu Z, Wang KZ, Huang N, et al. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res 2001;61:478-81. (Pubitemid 32128601)
28. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008;8:604-17.
29. Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;20:3772-84.
30. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-44.
31. Khatri A, Zhang B, Doherty E, Chapman J, Ow K, Pwint H, et al. Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. J Gene Med 2006;8:1086-96. (Pubitemid 44480401)
32. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
33. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009;15:167-70.
34. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231-47.
35. Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999;5:495-502. (Pubitemid 29220207)
36. Wang J, Zhang S, Rabinovich B, Bidaut L, Soghomonyan S, Alauddin MM, et al. Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action. Circ Res 2010;106:1904-11.
37. Zannad F, Rossignol P, Iraqi W. Extracellular matrix fibrotic markers in heart failure. Heart Fail Rev 15;319-29.
38. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
39. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001;33:357-69. (Pubitemid 32324004)
40. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010;468:824-8.
41. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468:829-33.
42. Bautch VL. Cancer: tumour stem cells switch sides. Nature 2010;468:770-1.